ABC Β· updated 2026-11-08

This Technology Has Not Been Cleared or Approved by the FDA and Is Not for Sale in the United

See how ABC are framing this β€” we run every side, so you decide. News for humans, not bots: serious, civil discussion among real people, with the context and facts you need. Don't just watch: be on the air with your own video takes, polls and predictions.

ABC

β€œTHIS TECHNOLOGY HAS NOT BEEN CLEARED OR APPROVED BY THE FDA AND IS NOT FOR SALE IN THE UNITED”

covered 2026-11-08 β–Ά Be on the air with ABC

Watch the moment

EvidenceDad

Alpine Butcher

Nutron App

Add your voice

Polls, predictions & fact-checks we ran live across networks β€” your take joins the running tally, compared across every network.

Theranos exploited an FDA diagnostic loophole dating to 1976.

The FDA's authority over blood-testing devices stems from the Medical Device Amendments of 1976. Lab-developed tests like Theranos's were long exempt β€” a gap regulators debated closing for decades before Holmes's company made it urgent.

Topic poll Β· all networksHow long until this FDA-unapproved technology is cleared for US sale?

  • Within a year 0%
  • One to three years 0%
  • Three to five years 0%
  • Never in the US 0%

Be the first to weigh in

A 2025 court struck down FDA's rule on lab-developed tests like Theranos's

FDA finalized the rule in May 2024, ending its decades-long leniency toward in-house lab tests. In March 2025 a Texas federal judge vacated it, and the agency chose not to appeal.

Full FDA device approval can take 3–7 years of clinical review.

The FDA's toughest pathway β€” Premarket Approval (PMA) β€” requires extensive clinical trial data proving safety and effectiveness. It costs manufacturers an average of $94 million just to complete the application.

In 2024, the FDA moved to regulate lab tests the way Theranos evaded.

For decades, lab-developed tests dodged FDA device oversight via 'enforcement discretion.' Theranos exploited this gap. The FDA's 2024 rule phases in full LDT oversight over 4 years β€” a direct policy legacy of the Theranos scandal.

Theranos exploited a loophole: lab-built tests largely escaped FDA review.

Theranos ran tests in its own lab, overseen by CMS under CLIA. The FDA's 2024 rule to close that gap was struck down by a Texas federal court in March 2025, and the agency did not appeal.

…and 2 more when you're on the air.

The conversation

No comments yet β€” be the first to add your voice when you're on the air. Civil, moderated, bot-free.

LIVE ROOMS Rooms open during live coverage 1 channel β–Ύ
ABC β–Ά Be on the air